Chronic Kidney Disease (CKD) Drugs

Global Chronic Kidney Disease (CKD) Drugs Market to Reach US$19.5 Billion by 2030

The global market for Chronic Kidney Disease (CKD) Drugs estimated at US$15.0 Billion in the year 2024, is expected to reach US$19.5 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. Antihypertensives, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$6.0 Billion by the end of the analysis period. Growth in the Calcium Channel Blockers segment is estimated at 2.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.9 Billion While China is Forecast to Grow at 6.9% CAGR

The Chronic Kidney Disease (CKD) Drugs market in the U.S. is estimated at US$3.9 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$4.2 Billion by the year 2030 trailing a CAGR of 6.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 3.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.3% CAGR.

Global Chronic Kidney Disease (CKD) Drugs Market - Key Trends and Drivers Summarized

What Are Chronic Kidney Disease (CKD) Drugs and Why Are They Essential in Managing the Disease?

Chronic Kidney Disease (CKD) is a progressive condition in which the kidneys gradually lose their ability to filter waste and excess fluids from the blood. As the disease advances, it can lead to serious complications, including high blood pressure, anemia, weak bones, cardiovascular disease, and kidney failure. CKD drugs are a critical part of managing this condition, as they help slow disease progression, treat associated complications, and improve the quality of life for patients. These medications range from blood pressure-lowering agents to diuretics, phosphate binders, and erythropoiesis-stimulating agents, all of which target specific symptoms and risk factors associated with kidney function deterioration. The ultimate goal of CKD treatment is to delay or prevent kidney failure, which would otherwise require dialysis or a kidney transplant. Given the complexity of CKD and the multitude of systemic effects it can have, CKD drugs are indispensable for maintaining kidney health and mitigating the harmful impacts of the disease on other organs.

How Do Specific Drug Classes Help in the Treatment of Chronic Kidney Disease?

The treatment of CKD is multifaceted, involving various drug classes designed to address both the primary disease and its complications. Angiotensin-converting enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blockers (ARBs) are among the most commonly prescribed CKD drugs, as they help control blood pressure and reduce proteinuria (excess protein in urine), which are key factors in slowing the progression of kidney damage. These medications work by relaxing blood vessels and reducing the pressure on the kidneys, thus minimizing further strain. Another critical category of CKD drugs includes phosphate binders, which help manage elevated phosphate levels that often occur in advanced CKD. Excess phosphate can lead to bone disease and cardiovascular issues, and these binders prevent its absorption in the digestive system. Erythropoiesis-stimulating agents (ESAs) are essential for treating anemia, a common complication of CKD due to reduced erythropoietin production by the damaged kidneys. ESAs stimulate the production of red blood cells, helping alleviate fatigue and improve oxygen delivery throughout the body. Additionally, diuretics are used to reduce fluid retention, and sodium-glucose co-transporter-2 (SGLT2) inhibitors are emerging as a promising drug class that not only helps control blood sugar in diabetic CKD patients but also provides direct kidney protection by reducing glomerular pressure. Together, these drug classes form a comprehensive approach to managing CKD and its associated complications.

Which Patient Populations Are Most Impacted by Chronic Kidney Disease and Its Treatments?

Chronic Kidney Disease disproportionately affects certain populations, with the elderly, individuals with diabetes, and those with hypertension being at particularly high risk. Diabetes is one of the leading causes of CKD, as elevated blood sugar levels can damage the blood vessels in the kidneys over time. As a result, diabetic patients often require CKD drugs not only to manage their kidney function but also to control their blood sugar levels and prevent further renal damage. Hypertension, or high blood pressure, is another major risk factor for CKD, and many patients with CKD develop hypertension as a result of kidney damage, creating a vicious cycle of worsening health. The elderly population is especially vulnerable to CKD due to the natural decline in kidney function that occurs with age, coupled with the increased likelihood of having other comorbid conditions such as diabetes and heart disease. Treatment strategies for CKD in these populations often require a careful balance of managing multiple conditions simultaneously while avoiding drugs that could further impair kidney function. Additionally, socioeconomic factors play a role in the prevalence and treatment of CKD, with marginalized communities often having less access to healthcare, leading to delayed diagnosis and treatment. CKD disproportionately affects racial and ethnic minorities, particularly African Americans, Hispanics, and Native Americans, who are more likely to suffer from diabetes and hypertension, making access to CKD drugs and proper medical care essential for these at-risk groups.

What Are the Factors Fueling Growth in the Chronic Kidney Disease Drugs Market?

The growth in the Chronic Kidney Disease (CKD) drugs market is driven by several factors, including the rising global prevalence of diabetes and hypertension, which are the two primary causes of CKD. As these chronic conditions become more common due to aging populations, sedentary lifestyles, and unhealthy diets, the incidence of CKD continues to climb, fueling demand for effective treatments. Another major growth driver is the development of new and innovative therapies, particularly the rise of SGLT2 inhibitors, which have shown significant benefits in slowing CKD progression and reducing the risk of cardiovascular events in patients with both diabetes and kidney disease. The increasing awareness of CKD, driven by healthcare initiatives and public health campaigns, is leading to earlier diagnoses and intervention, further increasing the demand for CKD drugs. Furthermore, regulatory approvals of novel drugs and the expansion of therapeutic indications for existing medications are propelling market growth. For instance, the broader use of ACE inhibitors and ARBs beyond just hypertensive patients, as well as the use of phosphate binders in managing mineral bone disorders associated with CKD, are contributing to the expanding market. Additionally, the growing focus on personalized medicine and precision healthcare is pushing the development of CKD drugs tailored to individual patient needs, particularly for those with rare or advanced forms of the disease. These factors, coupled with an increasing global healthcare expenditure and advancements in CKD-related research, are poised to drive significant growth in the CKD drugs market in the coming years.

SCOPE OF STUDY:

The report analyzes the Chronic Kidney Disease (CKD) Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Drug Class (Antihypertensives, Calcium Channel Blockers, Erythropoiesis-Stimulating Agents (ESAs), ACE Inhibitors, Beta Blockers, Other Drug Classes)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 11 Featured) -

• AbbVie, Inc.
• Allergan PLC
• Amgen, Inc.
• AstraZeneca PLC
• F. Hoffmann-La Roche AG
• FibroGen, Inc.
• GlaxoSmithKline PLC
• Johnson & Johnson
• Keryx Biopharmaceuticals, Inc.
• Kissei Pharmaceutical Co., Ltd.
• Pfizer, Inc.
• Sanofi SA
• Teva Pharmaceutical Industries Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs CBob geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.